Article Text

Download PDFPDF
GM-008 Economic valuation of losses due to drug leftovers: Case of tenecteplase
  1. W Enneffah1,
  2. MA El Wartiti1,
  3. F Berdi1,
  4. A Cheikh2,
  5. N Cherkaoui3,
  6. A Bennana4
  1. 1Mohammed v Military Teaching Hospital – Faculty of Medicine and Pharmacy- Mohammed v University, Clinical Pharmacy, RABAT, Morocco
  2. 2Cheikh Zaid University Hospital – Faculty of Medicine- Abulcasis International University of Health Sciences, Hospital Pharmacy, RABAT, Morocco
  3. 3Mohammed v Military Teaching Hospital – Faculty of Medicine and Pharmacy- Mohammed v University, Galenic Pharmacy, RABAT, Morocco
  4. 4Mohammed v Military Teaching Hospital – Faculty of Medicine and Pharmacy- Mohammed v University, Pharmaceutical Management, RABAT, Morocco


Background Optimising resource management is a major stake in health economics. In this way, managing costly injectable medications which are administered ‘dose by weight’ is a considerable concern to hospital pharmacists. Tenecteplase is one of the drugs whose use is likely to generate losses as only the 10 000 IU presentation is marketed in our country, and vials are often not wholly used.

Purpose To evaluate product losses at our hospital and the shortfall due to the non-commercialisation of other tenecteplase dosages in our country.

Material and methods This was a prospective study over a period of 1 year (from 4 January 2014 to 3 January 2015), focusing on 10 000 IU tenecteplase vials that were reconstituted and used in our hospital’s cardiology and emergency departments. Evaluation of leftovers was performed both by volumetric method and by weighing.

Results For the 50 vials studied over the study period, the volume of unused reconstituted drug leftovers varied between 0 ml and 4.8 mL per vial, with an average of 1.99 mL and a total volume of 99.32 mL. The financial study reported the results presented in table 1.

Abstract GM-008 Table 1

Conclusion The losses estimated at 19.86% of the budget dedicated to the purchase of tenecteplase at our hospital reflects the need for marketing of other dosages that are already available in other countries (6000 IU and 8000 IU). In the meantime, as some studies have shown the possibility of aliquoting and conserving reconstituted tenecteplase, it would be advisable to set up a centralised unit for sterile preparation of customised doses that would achieve savings on tenecteplase as well as on other expensive injectable products.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.